Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The source filing: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed July 30, 2026. Open the filing →
- Filed
- Jul 30, 2026, 9:06 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-050845
FAQ
- What is Madrigal Pharmaceuticals, Inc.'s D&A?
- Madrigal Pharmaceuticals, Inc. (MDGL) reported D&A of $381K in Q2 2026.
- How has Madrigal Pharmaceuticals, Inc.'s D&A changed year-over-year?
- Madrigal Pharmaceuticals, Inc.'s D&A increased by 1.1% year-over-year, from $377K to $381K.
- What is the long-term trend for Madrigal Pharmaceuticals, Inc.'s D&A?
- Over 4 years (2021 to 2025), Madrigal Pharmaceuticals, Inc.'s D&A has grown at a 38.9% compound annual growth rate (CAGR), from $405K to $1.51M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Madrigal Pharmaceuticals, Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude